KOSKI ROBERT C 4
4 · ORAGENICS INC · Filed Dec 13, 2024
Insider Transaction Report
Form 4
ORAGENICS INCOGEN
KOSKI ROBERT C
Director10% Owner
Transactions
- Conversion
Series B Convertible Preferred Stock
2024-12-11−1,500,000→ 0 total(indirect: See Footnote)→ Common Stock (5,000 underlying) - Conversion
Common Stock
2024-12-11+5,000→ 23,367 total(indirect: See Footnote)
Holdings
- 27,940
Common Stock
Footnotes (3)
- [F1]Represents shares owned by the Koski Family Limited Partnership ("KFLP"). The reporting person serves as one of the general partners of the KFLP and disclaims beneficial ownership of the securities reflected as held by the KFLP except to the extent of the reporting person's pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.
- [F2]Represents the full conversion of Series B Convertible Preferred Stock ("Series B") held by the KFLP into shares of common stock, pursuant to, and in accordance with, the certificate of designation for the Series B.
- [F3]The Series B was convertible into common stock at any time and had no expiration date. The Series B was issued on November 8, 2017, with an original issue price of $0.50 per share. On January 19, 2018, the Issuer effected a 1-for-10 reverse stock split, and on January 20, 2023, the Issuer effected a one-for-sixty reverse stock split, which collectively resulted in an adjusted conversion price of $300.00 per share.